RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis
T Aksamit, A De Soyza, TJ Bandel… - European …, 2018 - Eur Respiratory Soc
We evaluated the efficacy and safety of ciprofloxacin dry powder for inhalation (DPI) in
patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous …
patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous …
RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis
T Aksamit, A De Soyza, TJ Bandel… - The European …, 2018 - pubmed.ncbi.nlm.nih.gov
We evaluated the efficacy and safety of ciprofloxacin dry powder for inhalation (DPI) in
patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous …
patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous …
RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
T Aksamit, A De Soyza, TJ Bandel… - The European …, 2018 - europepmc.org
We evaluated the efficacy and safety of ciprofloxacin dry powder for inhalation (DPI) in
patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous …
patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous …
[PDF][PDF] RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis
T Aksamit, A De Soyza, TJ Bandel, M Criollo, JS Elborn… - Eur Respir J, 2018 - qdcxjkg.com
We evaluated the efficacy and safety of ciprofloxacin dry powder for inhalation (DPI) in
patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous …
patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous …
RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
T Aksamit, A Soyza, TJ Bandel, M Criollo, JS Elborn… - 2018 - cabidigitallibrary.org
We evaluated the efficacy and safety of ciprofloxacin dry powder for inhalation (DPI) in
patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous …
patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous …
[引用][C] RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis
T Aksamit, S De, TJ Bandel, M Criollo… - European Respiratory …, 2018 - eprints.ncl.ac.uk
We evaluated the efficacy and safety of Ciprofloxacin Dry Powder for Inhalation (DPI) in
patients with non-cystic fibrosis bronchiectasis (NCFB),≥ 2 exacerbations in the previous …
patients with non-cystic fibrosis bronchiectasis (NCFB),≥ 2 exacerbations in the previous …
[PDF][PDF] RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis
T Aksamit, A De Soyza, TJ Bandel, M Criollo, JS Elborn… - Eur Respir J, 2018 - qdcxjkg.com
We evaluated the efficacy and safety of ciprofloxacin dry powder for inhalation (DPI) in
patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous …
patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous …